Vessels That Encapsulate Tumor Clusters (VETC) Pattern Is a Predictor of Sorafenib Benefit in Patients with Hepatocellular Carcinoma
Sign Up to like & getrecommendations! Published in 2018 at "Hepatology"
DOI: 10.1002/hep.30366
Abstract: Sorafenib is the most recommended first‐line systemic therapy for advanced hepatocellular carcinoma (HCC). Yet there is no clinically applied biomarker for predicting sorafenib response. We have demonstrated that a vascular pattern, named VETC (Vessels that… read more here.
Keywords: benefit; vetc; sorafenib benefit; tumor clusters ... See more keywords